The globalization of risk and risk perception: Why we need a new model of risk communication for vaccines

Drug Safety

Volumn 35, Issue 11, 2012, Pages 1053-1059

  Larson, Heidi ^a   Brocard Paterson, Pauline ^a   Erondu, Ngozi ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Human papillomavirus vaccine; Measles mumps and rubella virus vaccine; Risk management; Vaccines.

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; VACCINE; WART VIRUS VACCINE;

ASEPTIC MENINGITIS; AUTISM; DRUG SAFETY; FEAR; HUMAN; IMMUNIZATION; INDIA; INTERNET; MODEL; POLICY; POLITICS; PRIORITY JOURNAL; RELIGION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK COMMUNICATION; RISK MANAGEMENT; RISK MITIGATION; RISK PERCEPTION; TRUST; UNITED KINGDOM;

COMMUNICATION; HUMANS; IMMUNIZATION PROGRAMS; INTERNATIONALITY; MEASLES-MUMPS-RUBELLA VACCINE; MODELS, THEORETICAL; RISK ASSESSMENT; VACCINATION; VACCINES;

EID: 84867511411     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11635880-000000000-00000     Document Type: Review

References (51)

1. National Research Council. Improving risk communication. Washington, DC: National Academy Press, 1989
2. Fischhoff B. Risk perception and communication unplugged: twenty years of progress. Risk Analysis 1995; 15 (2): 137-45
3. Slovic P. Perception of risk. Science 1987; 236: 280-5
4. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing and managing adverse reactions: benefit and risk communication. MMWR Recomm Rep 2011; 60 (2): 1-64
5. Leach M, Fairhead J. Vaccine anxieties: global science, child health and society. London: Earthscan, 2007
6. Wildavsky A, Dake K. Theories of risk perception: who fears what and why? Daedalus 1990; 119 (4): 41-60
7. Kaler A. Health interventions and the persistence of rumour: the circulation of sterility stories in African public health campaigns. Soc Sci Med 2009; 68: 1711-9
8. Evans G, Bostrom A, Johnston RB, et al., editors. Risk communication and vaccination. Washington, DC: Institute of Medicine, National Academy Press, 1997
9. Pidgeon N, Kasperson R, Slovic P. The social amplification of risk. London: Cambridge University Press, 2003
10. WHO. World health report: reducing risks, increasing healthy lives. Geneva: WHO, 2002
11. Sandman PM. Responding to community outrage: strategies for effective risk communication. Fairfax (VA): American Industrial Hygiene Association, 1993
12. Sandman PM. Hazard versus outrage in the public perception of risk. In: Covello VT, McCallum DB, Pavlova MT, editors. Effective risk communication: the role and responsibility of government and nongovernment organizations. New York (NY): Plenum Press, 1989: 45-9
13. Slovic P, Finucane ML, Peters E, et al. Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk Anal 2004; 24 (2): 311-22
14. Yahya M. Polio vaccines-difficult to swallow: the story of a controversy in Northern Nigeria. IDS working paper 261 [online]. Available from URL: http://www.ids.ac.uk/files/Wp261.pdf [Accessed 2012 Apr 17]
15. Jegede AS. What led to the Nigerian boycott of the polio vaccination campaign? PLOS Medicine 2007 Mar; 4 (3): e73
16. Obregon R, Waisbord S. The complexity of social mobilization in health communication: top-down and bottom-up experiences in polio eradication. J Health Commun 2010; 15: 25-47
17. Larson H, Brocard P, Garnett G. The India HPV vaccine suspension. Lancet 2010; 376 (9741): 572-3
18. Gangarosa EJ, Galazka AM, Wolde CR, et al. Impact of anti-vaccination movements on pertussis control: the untold story. Lancet 1998; 351: 356-61
19. WHO. EPI brief (February 2012). Geneva: WHO, 2012
20. WHO/UNICEF. Joint statement: global plan for reducing measles mortality 2006-2010 [online]. Available from URL: http://www.who.int/immunization- delivery/adc/measles/Measles%20Global%20Plan-Eng.pdf [Accessed 2012 Mar 27]
21. Mnookin S. The panic virus. New York: Simon and Shuster, 2011
22. Elliman D, Bedford H. MMR: where are we now? Arch Dis Child 2006; 92 (12): 1055-7
23. Larson H, Heymann D. Public health response to influenza A (H1N1) as an opportunity to build public trust. JAMA 2010; 303 (3): 271-2
24. Betraying the public over nvCJD risk [editorial]. Lancet 1996; 348 (9041): 1529
25. UK Department of Health. NHS immunisation statistics, England: 1997-1998 (table 2) [online]. Available from URL: http://www.dh.gov.uk/en/ Publicationsandstatistics/Statistics/StatisticalWorkAreas/Statisticalhealthcare/ DH-4016221 [Accessed 2012 Mar 12]
26. UK Department of Health. NHS immunisation statistics, England: 2010-11. Immunisations received by first and second birthday [online]. Available from URL: http://www.ic.nhs.uk/statistics-and-data-collections/health-andlifestyles/ immunisation/nhs-immunisation-statistics-england-2010-11 [Accessed 2012 Mar 12]
27. Offit P, Coffin S. Communicating science to the public: MMR vaccine and autism. Vaccine 2003; 22 (1): 1-6
28. Madsen KM, Hviid A, Vestergaard M, et al. A populationbased study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347: 1477-82
29. Wilson K, Mills E, Ross C, et al. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 2003; 157 (7): 628-34
30. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatr 2005; 46 (6): 572-9
31. Parker SP, Schwartz B, Todd J, et al. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004; 114 (3): 793-804
32. Katz S. Has the measles-mumps-rubella vaccine been fully exonerated? Pediatrics 2006; 118 (4): 1744-5
33. Kirkland A. Credibility battles in the autism litigation. Soc Stud Sci 2012; 42 (2): 237-61
34. Wakefield AJ. Callous disregard: autism and vaccines-the truth behind a tragedy [online]. Available from URL: http://www.callous-disregard.com/[Accessed 2012 Apr 24]
35. Pearce A, Law C, Elliman D, et al., Millennium Cohort Study Child Health Group. Factors associated with uptake of measles, mumps, and rubella vaccine (MMR) and use of single antigen vaccines in a contemporary UK cohort: prospective cohort study. BMJ 2008; 226 (7647): 754-7
36. Casiday R, Cresswell T, Wilson D, et al. A survey of UK parental attitudes to theMMRvaccine and trust in medical authority. Vaccine 2006; 24 (2): 177-84
37. Casiday R. Children's health and the social theory of risk: insights from the British measles, mumps and rubella (MMR) controversy. Soc Sci Med 2007; 65 (5): 1059-70
38. Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998-2005: inevitable community outrage or a failure of risk communication? Vaccine 2006; 24 (18): 3921-8
39. Messenger S. Melanie's marvellous measles. Australia: Nature Matters, 2010
40. Black S, Rappuoli R. A crisis of public confidence in vaccines. Sci Transl Med 2010; 2 (61): 61mr1
41. Shetty P. Experts concerned about vaccination backlash. Lancet 2010 Mar 20; 375 (9719): 970-1
42. Poethko-Muller C, Ellert U, Kuhnert R, et al. Vaccination coverage against measles in German-born and foreign-born children and identification of unvaccinated subgroups in Germany. Vaccine 2009 Apr 28; 27 (19): 2563-9
43. CDC. Measles: United States, January-May 20, 2011. MMWR 2011; 60 (20): 666-8 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm60 20a7.htm?s-cid=mm6020a7-w [Accessed 2012 Mar 22]
44. WHO. Weekly epidemiological record. Progress in global measles control, 2000-2010 [online]. Available from URL: http://www.who.int/wer/2012/wer8705.pdf [Accessed 2012 Mar 27]
45. WHO. Weekly epidemiological record. Measles outbreaks and progress towards meeting measles pre-elimination goals: WHO African region, 2009-2010 [online]. Available from URL: http://www.who.int/wer/2011/wer8614.pdf [Accessed 2012 Mar 27]
46. WHO. Global elimination of measles: report by the Secretariat. WHO Executive Board, 125th Session; 2009 April 16. Report No:EB125/4 [online]. Available from URL: http://apps.who.int/gb/ebwha/pdf-files/EB125/B125-4-en. pdf [Accessed 2012 Aug 28]
47. Woonink F. Objections against vaccination: the perspective of those who refuse. National Institute for Public Health and the Environment, the Netherlands, 2009 [online]. Available from URL: http://www.rivm.nl/en/Images/ 000652% 20Bezw%20tegen%20vacc%20EN-tcm13-67802.pdf [Accessed 2012 Sept 18]
48. CDC. Measles: United States, 2011. MMWR 2012; 61 (15): 253-7 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6115a1.htm#tab [Accessed 2012 Apr 21]
49. Burnett RJ, Larson HJ, Moloi MH, et al. Addressing public questioning and concerns about vaccination in South Africa: a guide for healthcare workers. Vaccine 2012; 30 Suppl. 3: C72-8
50. Waisbord S, Larson H. Why invest in communication for immunization? Evidence and lessons learned. A joint publication of the Health Communication Partnership, Johns Hopkins Bloomberg School of Public Health (Baltimore) and UNICEF (New York) [online]. Available from URL: http://www. globalhealthcommunication.org/tool-docs/21/why-invest-in-communication-for- immunization.pdf [Accessed 2012 Mar 27]
51. Larson H, Cooper LZ, Eskola J, et al. Addressing the vaccine confidence gap. Lancet 2011; 378 (9790): 526-35